.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

XOFIGO Drug Profile

« Back to Dashboard
Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA. It is available from one supplier. There is one patent protecting this drug.

This drug has thirty-one patent family members in twenty-one countries.

The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.

Summary for Tradename: XOFIGO

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Drug Prices: :see details

Pharmacology for Tradename: XOFIGO

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
XOFIGO
radium ra-223 dichloride
SOLUTION;INTRAVENOUS203971-001May 15, 2013RXYes6,635,234► subscribe ► subscribe
Bayer Hlthcare
XOFIGO
radium ra-223 dichloride
SOLUTION;INTRAVENOUS203971-001May 15, 2013RXYes► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: XOFIGO

Country Document Number Estimated Expiration
China1767078► subscribe
Spain2268888► subscribe
New Zealand534618► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: XOFIGO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1140212/01Switzerland► subscribePRODUCT NAME: RADIUM RA-223; REGISTRATION NO/DATE: SWISSMEDIC 62732 29.08.2014
00666Netherlands► subscribePRODUCT NAME: RADIUM-223, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/13/873/001 20131113
C0038France► subscribePRODUCT NAME: RADIUM 223 AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER LE DICHLORURE DE RADIUM 223; REGISTRATION NO/DATE: EU/1/13/873 20131113
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc